Undeniable Need for Ultrafast-Acting Insulin: The Pediatric Perspective

Eda Cengiz, M.D., M.H.S.

Abstract

Insulin therapy in youth with type 1 diabetes mellitus (T1DM) poses a special challenge because childhood is an unsteady state with increasing weight, height, and caloric needs, leading to varying insulin requirements. The current rapid-acting insulin analogs are not as fast and short-acting as needed to meet these challenges. This review describes the unique characteristics of insulin action in youth with T1DM based on previously published euglycemic clamp studies. It also explains the rationale behind the need for ultrafast-acting insulins to advance open- and closed-loop insulin therapy for the pediatric population with diabetes. Lastly, it briefly summarizes ongoing and future projects to accelerate insulin action in youth with T1DM.


Author Affiliation: Division of Pediatric Endocrinology and Diabetes, Yale University School of Medicine, New Haven, Connecticut

Abbreviations: (CL) closed-loop, (DCCT) Diabetes Control and Complications Trial, (PD) pharmacodynamics, (PK) pharmacokinetics, (RAI) rapid-acting insulin analog, (T1DM) type 1 diabetes mellitus, (UFI) ultrafast-acting insulin

Keywords: children, closed-loop, diabetes, hyperglycemia, hypoglycemia, insulin analog, ultrafast-acting insulin

Corresponding Author: Eda Cengiz, M.D., M.H.S., Division of Pediatric Endocrinology and Diabetes, Yale University School of Medicine, 333 Cedar St., PO Box 208064 New Haven, CT 06520; email address Eda.Cengiz@yale.edu